Croston Glenn E
ACADIA Pharmaceuticals, 3911 Sorrento Valley Blvd, San Diego, CA 92121, USA.
Trends Biotechnol. 2002 Mar;20(3):110-5. doi: 10.1016/s0167-7799(02)01906-6.
The availability of genomic information significantly increases the number of potential targets available for drug discovery, although the function of many targets and their relationship to disease is unknown. In a chemical genomic research approach, ultra-high throughput screening (uHTS) of genomic targets takes place early in the drug discovery process, before target validation. Target-selective modulators then provide drug leads and pharmacological research tools to validate target function. Effective implementation of a chemical genomic strategy requires assays that can perform uHTS for large numbers of genomic targets. Cell-based functional assays are capable of the uHTS throughput required for chemical genomic research, and their functional nature provides distinct advantages over ligand-binding assays in the identification of target-selective modulators.
基因组信息的可得性显著增加了药物研发中潜在靶点的数量,尽管许多靶点的功能及其与疾病的关系尚不清楚。在化学基因组学研究方法中,基因组靶点的超高通量筛选(uHTS)在药物研发过程早期、靶点验证之前进行。靶点选择性调节剂随后提供药物先导物和药理研究工具来验证靶点功能。有效实施化学基因组学策略需要能够对大量基因组靶点进行uHTS的检测方法。基于细胞的功能检测能够满足化学基因组学研究所需的uHTS通量,并且其功能特性在识别靶点选择性调节剂方面比配体结合检测具有明显优势。